Introduction
Conventional therapy in chronic lymphocytic leukaemia (CLL) is not curative, partly because there is almost always detectable CLL after therapy. Recent therapeutic approaches, such as rituximab combined with purine analogues, 1,2 alemtuzumab as consolidation 3, 4 or stem cell transplantation, 5, 6 are associated with improved response rates with up to 70% of patients achieving an National Cancer Institute-complete remission after Fludarabine/Cyclophosphamide/Rituximab (FCR). 7, 8 In addition, these approaches have been associated with eradication of detectable disease in a significant proportion of patients. Several studies demonstrate that patients with CLL who achieve an eradication of detectable minimal residual disease (MRD) using a highly sensitive technique have prolonged survival irrespective of the therapy used to achieve this goal. [9] [10] [11] Patients achieving an MRD-positive complete response show the same overall survival as those achieving only a partial response; sustained remissions only occur in patients achieving an MRDnegative complete response. 12 Therefore MRD is increasingly being used as an end point for therapeutic trials, and several studies are now using the assessment of MRD to define the duration of therapy.
Approaches using allele-specific oligonucleotide polymerase chain reaction (ASO-PCR) to the immunoglobulin gene of the B-CLL cell are generally accepted to show the highest sensitivity for MRD detection. However, more recent four-colour approaches show sensitivities nearing that of ASO-PCR 6, 11, 13 with lower expense and more rapid provision of results. These approaches are dependent on the differential expression of proteins by CLL and normal B-cells, particularly CD5, CD79b and CD20. CD20 provides the best separation of normal mature B cells from CLL cells, as the former have very strong homogeneous expression, whereas CLL cells show weak expression. 11 However, treatment with rituximab-containing regimens results in masking of the CD20 epitope and/or downregulation of the protein on the cell surface of normal B-cells. [14] [15] [16] This makes it impossible to differentiate normal B cells from CLL cells on the basis of CD20 expression. The apparent lack of CD20 expression by normal B-cells may continue for several months. As such, current MRD-flow approaches involving CD20 analysis have a poor sensitivity in patients treated with rituximab.
Alternative approaches have been identified, including the CD22/CD23/CD19/CD5 combination reported by Sanchez et al. 17 However, there is significant overlap between CLL cells and normal CD5 þ 23 þ B-cells which are particularly prevalent after effective therapy. 11 Therefore, in cases which have stronger CD22 expression the CD22/CD23/CD19/CD5 combination is no longer disease-specific: ideally, CD22 would be combined with other antibodies that maintain separation of CLL cells from normal B-cells even when CD22 expression is near normal. Identification of such synergistic combinations requires reevaluation of previously identified markers in combination with novel or rarely reported markers such as CD31, CD39, CD47, CD63 and CD81. [18] [19] [20] [21] [22] Ideally an MRD assay would also be applied to pretreatment/ diagnostic samples, in order to ensure that each patient is suitable for monitoring with the specific assay. An extension of this goal is that a diagnostic panel would comprise of the MRD assays for each B-cell disorder. Therefore the first aim was to identify antibodies that could separate CLL cells from normal B-cells as well as from other B-cell disorders. To achieve this we incorporated antibodies in our initial panel that are currently used in diagnosis of other disorders (e.g. CD11c and CD103 for Hairy Cell Leukaemia). The antibodies identified from the first round of screening could then be used for the development of disease-specific assays for CLL as well as for other B-cell disorders. The simultaneous analysis of large numbers of antigens is complex but recent studies have demonstrated that it is possible to use the software developed for messenger RNA microarray analysis to facilitate this approach. 23 We have used this software to provide a systematic approach for MRD flow assay development, specifically a combination that is suitable for detection of CLL cells in patients undergoing therapy with rituximab.
Methods

Patients
Samples were assessed from patients with CLL (marrow n ¼ 34, lymph node n ¼ 1 and blood n ¼ 14), Waldenstroms macroglobulinaemia (marrow n ¼ 3), mantle cell lymphoma (marrow n ¼ 2, blood n ¼ 1), follicular lymphoma (lymph node n ¼ 2, marrow n ¼ 1), diffuse large cell lymphoma (lymph node n ¼ 1, marrow n ¼ 2) and normal controls (marrow n ¼ 15, lymph node n ¼ 3 and blood n ¼ 3). For neoplastic cases, disorders were diagnosed according to standard World Health Organization (WHO) criteria; patients were at presentation for non-CLL disorders. CLL patients were either at presentation (n ¼ 13) or relapse at least 3 months from prior therapy (n ¼ 36). In all cases the samples showed complete replacement of the relevant B-lineage compartment with neoplastic cells. All samples were taken with full-informed patient consent for investigation of a known or suspected haematological disorder. Treatment with the FCR regimen was performed as reported previously. 8 Samples were anonymized before extended analysis was performed, according to the requirements of the local ethical review committee. The study conforms to the tenets of the Declaration of Helsinki principle.
Flow cytometry
Leucocytes were prepared by incubation with a 10-fold excess of ammonium chloride (8.6 g/l in distilled H 2 0) for 5 min, and washed twice in fluorescence-activated cell sorter (FACS)Flow (BD Biosciences, Oxford, UK) containing 0.3% bovine serum albumin (Sigma, UK). Leucocytes (1 Â 10 6 ) were stained with 10 ml volumes of each pre-titred antibody per test for 20 min at 41C, and washed twice. Samples were acquired using a Becton Dickinson FACSort with CELLQuest v3.1 software (BD Biosciences, Oxford, UK).
The For the assessment of antigen expression during in vitro exposure to rituximab, leucocytes from a patient with marginal zone lymphoma (B cells 85% of leucocytes with strong CD20 expression) were prepared by ammonium chloride lysis as described above. Cells (10 6 ) were incubated with 100 ml of therapeutic antibody at serial 1:2 dilutions in FACSFlow from 1:10 to 1:5120 for 20 min. Cells were then washed twice and incubated with 10 ml of CD20 FITC IT and 10 ml CD19 PE-Cy5 H ; complete abrogation of CD20 binding occurred at dilutions up to 1:500. Leucocytes from the peripheral blood of six patients with active disease (499% of B cells were CLL phenotype and the absolute B-cell count was 410 Â 10 9 /l) were prepared by ammonium chloride lysis as described above. For each patient, three tubes containing 10 6 cells were incubated with 100 ml of therapeutic antibody at a 1:100 dilution, and three tubes containing 10 6 cells were incubated with 100 ml FACSFlow for 20 min. The cells were washed twice, and then incubated for 20 min with 10 ml CD19 PE-Cy5 H and either (i) 10 ml antirituximab FITC S or (ii) 10 ml anti-CD20 FITC IT ; or (iii) 10 ml each of CD81 FITC BD , CD22 PE BD and CD5 APC BD . Cells were again washed twice and at least 10 000 CLL cells were acquired and analysed.
For the assessment of antigen expression levels in a patient undergoing rituximab therapy, peripheral blood leucocytes were prepared by ammonium chloride lysis as described above. Cells (10 6 ) were incubated for 20 min with 10 ml CD19 PE-Cy5 
Data analysis
B cells were identified using a combined CD19 vs side scatter (SSC) and a forward scatter (FSC) vs SSC gate as reported previously.
11 B-progenitors or germinal centre cells were separated from mature or non-germinal centre B cells using an additional CD19 vs CD38 gate in normal bone marrow or lymph node samples, respectively. Geometric mean fluorescence intensity data for each antibody on each B-cell subset was recorded. The degree of overlap for expression of antigens was also assessed in specific cases: a region was set to enclose more than 95% of normal B-cells (either mature B-cells or B-progenitors) from at least three donors. The proportion of CLL cells falling within these regions was then calculated. The degree of overlap was defined as the percentage of CLL cells present within the normal B-cell region. Hierarchical clustering analysis and identification of proteins that were differentially expressed at a statistically significant level between B-cell subgroups were analysed using the DNA-Chip (dChip) v1.2 software. 24 For hierarchical cluster analysis, rows were standardized and distances pre-calculated; distance ¼ 1Àr (r is Pearson's); P-value threshold for calling significant clusters was 0.005 for proteins and 0.05 for samples. Selection of antibodies for further analysis was made using the compare samples function. The selection criteria were E/B41.5 or E/Bo1.5 (i.e. at least 1.5-fold difference in mean expression levels) and E-B450 or B-E450 (i.e. at least a 50 U difference in mean expression levels) where E ¼ experimental (i.e. CLL) expression and B ¼ baseline (i.e. normal mature B-cell and B-progenitor) expression.
Results
Identification of antigens that differentiate CLL cells from other neoplastic and normal B-cells
A panel containing 66 individual antibodies was assessed on a series of neoplastic B-lineage cells from a variety of disorders as well as from normal controls. Owing to the complexity of this analysis, the initial assessment was restricted to three samples from each normal and neoplastic B-lineage cell type. Protein expression levels, represented by geometric mean fluorescence intensity, were recorded and the data imported into the dChip analysis program. Figure 1 shows the unsupervised hierarchical clustering analysis for this data set. Some B-cell populations, such as CLL cells and normal B-progenitors, show a significant association at the Po0.005 level. Other B-cell disorders are associated to a lesser extent, for example many of the diffuse large cell lymphomas, follicular lymphomas and normal germinal centre B-cells. However, some B-lineage cells are incorrectly clustered, primarily because many of the antigens assessed are irrelevant and this weakens the association. Irrelevant antigens, defined as those that showed less than twofold expression above control (CD3) levels in all cases or less than 1.5-fold difference between cases, were excluded from further analysis. This left 30 antibodies for further study.
Iterative analysis to identify the antibodies providing maximal separation of CLL cells from normal B-cells
A series of experiments were performed to identify the optimal antibody combinations required to separate CLL cells from their normal counterparts. In each iteration, a progressively smaller and more focussed panel of antibodies were tested against a larger series of cases.
First the 'compare samples' function in dChip was used to identify antigens that showed significantly different expression (t-test Po0.05) between CLL cells and normal B-cells (both progenitor cells and mature B-cells). Then hierarchical clustering was performed for expression of the selected antigens on CLL cases only. The tree was cut (indicated by the vertical lines to the left of the heatmaps on Figure 2b and d) to yield three clusters. Within each cluster, the antigens with a median overlap in expression between CLL cells and normal mature/ progenitor B-cells of greater than 30% were excluded from further analysis with the exception that at least one antigen from each cluster was kept in order to provide antigens that would yield additive information when combined. This process is demonstrated in Figure 2 .
In the first stage, 30 antibodies were tested against seven CLL patients and seven normal bone marrow B-progenitor and mature B-cell samples (Figure 2a ). Of these, 14 antigens were not expressed at a significantly different level between CLL cells and normal B-cell. The remaining 16 antigens were assessed for differential expression between CLL patients (Figure 2b ). In the top cluster (CD20, CCR6, CD22, CD40, CD21, LAIR-1, CD24 and CD79b) all the antigens provided good separation of CLL cells from normal and all were selected. In the second cluster (CD69, CCR7 and CD27) and third cluster (CD23, CD25, CD81, CD31 and CD37) the antigens CD69, CD23, CD25 and CD31 were excluded from further analysis.
The remaining 12 antibodies were tested against 11 more CLL patients, four normal bone marrow samples and three normal peripheral blood samples, that is, 18 CLL patients in total, 14 normal mature B-cell and 11 normal B-progenitor samples in total (Figure 2c ). Four antigens (CCR7, CD24, CD37 and CD40) were excluded as the differential expression between CLL cells and normal B-cells was no longer significant. The remaining eight antigens were assessed for differential expression between CLL cases (Figure 2d ). In the first cluster (CD27 and CD81), CD27 was excluded owing to overlap with normal mature B-cells. In the second cluster (CCR6, CD20, CD22 and CD79b) and third cluster (CD21, LAIR-1), all the antigens showed a low degree of overlap and were selected for further analysis.
However, CCR6 was not tested further as owing to a batch variation, which meant that expression levels could not be compared with previous results
The remaining six antibodies were not tested on any more normal samples, as it was not possible to discern any difference in expression between normal B-cells from different samples, but were tested against a further eight CLL patients, that is, 26 CLL, 11 B-progenitor and 14 mature B-cell samples in total (Figure 2e ). All the antigens continued to show a significant difference in expression levels between CLL cells and normal B-cells. There were two major clusters, with CD81 in one cluster and the other antigens separated within the second, therefore further cluster analysis would not have been informative. The relative difference in expression if these antigens between CLL cells and normal mature B-cells and B-progenitors is shown in Figure 2f . In order to determine the optimal combination, bivariate overlap analysis was performed with CD81 in combination with the other antigens LAIR-1, CD21, CD22 and CD79b. The combination of CD81 with CD22 provided the lowest degree of overlap. Therefore the best four-colour combination suitable for patients treated with rituximab-containing regimens was identified by this approach to be CD81 vs CD22 vs CD19 vs CD5. Figure 3 shows the gating strategy for analysis of this combination and the normal patterns of CD81 vs CD22 expression in B-progenitors and mature B-cells relative to CLL cells.
Dilutional studies
The CD81/CD22/CD19/CD5 combination was next compared to previously reported combinations (CD20/CD79b/CD19/CD5 and CD20/CD38/CD19/CD5) in serial dilution analysis. CLL samples from three patients were diluted into normal bone marrow, using fluorochrome-labelled beads to accurately quantitate the relative dilution as reported previously. 11 The studies demonstrate that the CD81/CD22/CD19/CD5 combination has the same sensitivity and specificity as the previously reported combinations. An example of this analysis is shown in Figure 4 . 
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Discussion
This study has demonstrated a systematic approach for assessing large numbers of proteins with the aim of identifying diseasespecific combinations. The approach has identified a CLLspecific combination that is independent of CD20 expression and potentially applicable to MRD analysis for all treatment regimens including those that contain rituximab. Hierarchical cluster analysis is potentially of great value in classifying protein expression levels and has been used previously to identify different prognostic groups in patients with MDS. 25 The use of microarray software for protein expression profiling has several advantages over standard flow cytometric analysis: proteins that are differentially expressed both between and within many cellular subsets can be identified from a large group of test antigens simultaneously; proteins that may provide additive information when combined can be identified through cluster analysis; finally, the initial files can be re-analysed to check individual data points. This approach also has a significant advantage over gene expression profiling, as the cellular subsets can be specifically gated, so that information may be derived from the cell of interest only, and contaminating material can be excluded. In addition, several subsets can be analysed from within a single cytometry file, for example, data from plasma cells, B-progenitor cells and mature B-cells, can be derived from a single file.
In spite of the advantages it is necessary to use caution when applying such an analysis. The inclusion of irrelevant antigens may weaken clustering for associated samples, as seen in Figure 1 . Further problems may arise because the approach compares differences in expression to the overall mean expression for the samples tested. Weakly expressed antigens may be incorrectly identified owing to the variation that may be seen in autofluorescence and nonspecific binding between samples. For example, CCR7 is weakly expressed on CLL cells from a proportion of patients but does not appear to be expressed by any normal B-cells; although expression is weak, it is highly specific for aberrant cells and clearly identifiable by standard flow cytometric approaches, but this is not highlighted by the dChip analysis software. The converse of this is that some antigens that are not expressed by any samples may appear as being significantly overexpressed on cases with higher autofluorescence, such as diffuse large B-cell lymphoma (DLBL) cases. One possibility is to normalize expression data to background, but this may also introduce artefactual results. Another possibility is to compare the percentage of events positive relative to the control, rather than the level of expression. This may also be of value because using mean fluorescence intensity does not allow consideration of the range of expression. Many proteins have a broad range of expression on a particular cellular subset, and there may be significant overlap in expression level between two subsets with a similar mean/median expression. The disadvantage of using percentage expression data is that this information may be less sensitive for discrimination purposes. For example, both normal mature B-cells and CLL cells express CD20 above control/background, so on a percentage analysis both give a similar result; however, the level of CD20 is significantly lower on CLL cells compared to normal and therefore CD20 is one of the best antigens for discriminating CLL cells from normal in an MRD setting.
11
The approach used in this study does not identify new information about the value of an individual antibody for discriminating one cell subset from another: such information is best derived from conventional analysis. The value of this approach is in the identification of optimal combinations of antibodies, which is achieved by selecting at least one antibody from each cluster in the neoplastic cell expression profile for further analysis. This ensures the complementarity of the final antibody combination(s). Both CD22 and CD81 expression on CLL cells is usually lower than normal mature B-cells, but CLL cases with near-normal CD22 expression have lower CD81 expression and vice versa. In contrast, CLL cases with higher CD22 expression are also likely to have higher CD20, CD79b and CD21 expression; therefore combining these antigens would not improve the resolution of CLL cells from normal counterparts. Identifying complementary antigens is not a trivial issue considering the increasing range of potential antibodies and the increasing number of detectors available for flow cytometric analysis.
The assay that we have identified in this study has several advantages over previously identified flow cytometric assays: it is applicable to patients undergoing treatment with rituximabcontaining regimens; the single test is applicable to both peripheral blood and bone marrow samples; and the assay provides improved resolution in the small proportion of patients with strong CD20 expression. It is unlikely that this assay would be used as a single test for MRD assessment, as an optimal flow cytometric approach should have more than one test for residual disease to provide an internal control for the assay. The CD81/ CD22/CD19/CD5 combination has now been extensively tested in comparison with other combinations in a large multicentre study assessing several hundred samples and was one of three combinations identified from assessment of over 50 individual combinations as providing the most sensitive and specific combinations for CLL MRD analysis (Rawstron AC et al. Blood 2004; 104:15, abstract).
MRD assessment is highly relevant because conventional monitoring is insufficiently sensitive to discriminate outcome with recent therapeutic approaches. Until it is possible to compare the efficacy of therapeutic regimens directly in a standardized manner, progress in the development of effective treatment is hampered because trials performed in different centres or by different collaborative groups are difficult to compare. It is therefore important that both PCR and flow cytometric methods are identified that generate standardized comparable results.
In summary, we have developed a systematic approach using hierarchical clustering analysis to identify focussed diseasespecific antibody combinations starting from a large number of potential targets. In this case, we have developed a CLL-specific assay which is suitable for studying disease levels in CLL patients treated with rituximab-containing regimens and which is applicable to both peripheral blood and bone marrow analysis.
